Conférence
Conférence annuelle ESVONC (European Society of Veterinary Oncology) (Lyon, France) – Avril 2017 – “ Targeting CD22 in spontaneous diffuse large B-cell lymphoma bearing dogs : quantitative imaging (immuno-SPECT) and dosimetric approach in preparation of radioimmunotherapy (RIT) “ F. Morio1, N. Chouin1,2, F. Nguyen1, M. Berthaud2, M. Fusellier3, C. Bodet-Milin2,4, M. Roussel1, S. Becavin1, J. Abadie1, L. Ferrer2,5, C. Ibisch1,2, F. Davodeau2
Conférence EANM 2017 (Vienne, Autriche)- Octobre 2017 – « B-cell lymphoma radioimmunotherapy : effect of co-infusion of cold and radiolabelled antibody on absorbed doses to healthy tissues and tumours, a preclinical study in dogs ». F. Morio1,2, C. Ibisch1,2, F. Nguyen1,3, M. Berthaud2, J. Abadie1,3, A. Vidal5, M. Bourgeois2,4,5, K. Bernardeau7, S. Becavin1, M. Roussel1, L. Ferrer2,6, C. Bodet-Milin2,4, N. Chouin1,2, F. Davodeau2
J. Barbet, Conf invité Pretargeting in the Context of Theranostics and Companion Diagnostics, CME 5 : Theranostics and Companion Drugs, EANM, Vienna (Autriche) October 21-25, 2017
Chérel M, Anticorps monoclonaux : mise en place d’une filière nationale : le point de vue d’Arronax, 11e Journées du cancéropole Grand Ouest, Vannes, France, June 29-30 2017
PET Imaging criteria in Myeloma, Kraeber-Bodéré F, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018 (invited)
PET Imaging criteria in Myeloma, Bodet-Milin C, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018 (invited)
Efficacy of Astatine-211 radioimmunotherapy of Multiple Myeloma using an anti-mCD138 monoclonal antibody in a syngeneic murine model (OP-508). Gouard S, Chalopin B, Maurel C, Guérard F, Navarro L, Gestin JF, Chouin N, Haddad F, Alliot C, Kraeber-Bodéré F, Davodeau F, Chérel M . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
Biodistribution, Imaging and Metabolism Studies of 64-Copper Radiolabelled Monoclonal Antibody: Comparison of DOTA and TE1PA Chelating Agents in a Murine Model of Multiple Myeloma (OP-375). Navarro AS, Le Bihan T, Le Saëc P, Gouard S, Le Bris N, Bailly C, Saï-Maurel C, Chalopin B, Gestin JF, Chérel M, Tripier R, Faivre-Chauvet A. EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
PET Imaging of Multiple Myeloma: Comparison of 89Zr- and 64Cu-labeled anti-CD138 Conjugates to 64CuCl2 and 18F-FDG in a Preclinical Syngeneic Model (OP-040). Bailly C, Gouard S, Chalopin B, Carlier T, Maurel C, Remaud-Le Saëc P, Bourgeois M, Chouin N, Tripier R, Haddad F, Faivre-Chauvet A, Kraeber-Bodere F, Bodet-Milin C, Cherel M . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
Preliminary results of 68Ga-PSMA PET/CT prospective study in prostate cancer occult recurrence patients: diagnostic performance and impact on therapeutic decision-making (OP-042). Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis V, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
Why should we take care about occupational dosimetric impact when routine use of gallium-68 in nuclear medicine? A preliminary study (OP-238). Varmenot N, Ferrer L, Frindel M, Rauscher A, Baumgartner P, Delaunay F, Mathey A, Pitel C, Zulian H, Kraeber-Bodéré F, Denis A, Rousseau C . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018